← All stocks

Avalo Therapeutics, Inc.

AVTX Scheduled selling only
CIK 0001534120 #2500 in the set updated 17 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$1.66M
$0.00 on a plan · $1.66M straight out of an exercise
Sold at will
$0.00
0 of 6 sales
Net
−$1.66M
$0.00 against sales at will

By person

11 insiders · 6 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Sullivan Christopher Ryan
Chief Financial Officer
$1.63M (4) scheduled
−$1.63M
39,900
$703.03K
+3,322%
Doyle Mittie
Chief Medical Officer
$33.58K (2) scheduled
−$33.58K
51,776
$912.28K
+399.1%
NEIL GARRY ARTHUR
Chief Executive Officer
190,314
$3.35M
+317,090%
Riley Jennifer
Chief Strategy Officer
37,041
$652.65K
+451.1%
VARKI PAUL
Chief Legal Officer
32,576
$573.98K
+214.0%
KAPLAN GILLA
Director
6,333
$111.59K
Truex Samantha
Director
6,333
$111.59K
KANTOFF AARON
Director
6,333
$111.59K
Almenoff June Sherie
Director
4,167
$73.42K
Chan Mitchell
Director
3,166
$55.78K
Goldman Jonathan
Director
3,166
$55.78K

No percentages here. This company's share count has moved by a factor of 5.2 over the window, from 10,393,954 to 53,629,989 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Sullivan Christopher Ryan
10 Sep 2026
Chief Financial Officer
Sold after exercise
10,185
$17.62
$179.46K
Doyle Mittie
28 Aug 2026
Chief Medical Officer
Sold after exercise
679
$20.00
$13.58K
Sullivan Christopher Ryan
18 Aug 2026
Chief Financial Officer
Sold after exercise
31,031
$20.05
$622.32K
Doyle Mittie
17 Aug 2026
Chief Medical Officer
Sold after exercise
1,000
$20.00
$20.00K
Sullivan Christopher Ryan
17 Aug 2026
Chief Financial Officer
Sold after exercise
3,749
$19.94
$74.76K
Sullivan Christopher Ryan
17 Aug 2026
Chief Financial Officer
Sold after exercise
37,945
$19.85
$753.33K

What was left out

Form 4 filings counted 4
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 6
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 83,716
History held since 3 Oct 2016